- Home
- DCH vs NKTR Comparison
DCH vs NKTR Comparison
Compare DCH & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCH | NKTR |
|---|---|---|
| Founded | 1994 | 1990 |
| Country | United States | United States |
| Employees | 20000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1998 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DCH | NKTR |
|---|---|---|
| Price | $4.73 | $38.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $7.99 | ★ $133.08 |
| AVG Volume (30 Days) | ★ 4.7M | 660.2K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,836,700,000.00 | $307,711,000.00 |
| Revenue This Year | $83.80 | N/A |
| Revenue Next Year | $2.77 | $27.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $4.41 | $33.40 |
| 52 Week High | $8.75 | $109.00 |
Technical Indicators
Market Signals| Indicator | DCH | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 38.97 |
| Support Level | $4.44 | $35.61 |
| Resistance Level | $5.12 | $39.89 |
| Average True Range (ATR) | 0.26 | 1.58 |
| MACD | 0.02 | 0.96 |
| Stochastic Oscillator | 35.21 | 46.30 |
Price Performance
Historical ComparisonAbout DCH Dauch Corporation Common Stock
Dauch Corp is a world-wide Tier 1 Automotive Supplier, Dauch designs, engineers and manufactures Driveline and Metal Forming technologies to support electric, hybrid and internal combustion vehicles.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.